Cantu syndrome (CS) is caused by the gain of function mutations in the ABCC9 and KCNJ8 genes encoding, respectively, for the sulfonylureas receptor type 2 (SUR2) and the inwardly rectifier potassium channel 6.1 (Kir6.1) of the ATP-sensitive potassium (KATP) channels. CS is a multi-organ condition with a cardiovascular phenotype, neuromuscular symptoms, and skeletal malformations. Glibenclamide has been proposed for use in CS, but even in animals, the drug is incompletely effective against severe mutations, including the Kir6.1(wt/V65M). Patch-clamp experiments showed that zoledronic acid (ZOL) fully reduced the whole-cell KATP currents in bone calvaria cells from wild type (WT/WT) and heterozygous Kir6.1(wt/V65M)CS mice, with IC50 for ZOL block < 1 nM in each case. ZOL fully reduced KATP current in excised patches in skeletal muscle fibers in WT/WT and CS mice, with IC50 of 100 nM in each case. Interestingly, KATP currents in the bone of heterozygous SUR2(wt/A478V) mice were less sensitive to ZOL inhibition, showing an IC50 of similar to 500 nM and a slope of similar to 0.3. In homozygous SUR2(A478V/A478V) cells, ZOL failed to fully inhibit the KATP currents, causing only similar to 35% inhibition at 100 mu M, but was responsive to glibenclamide. ZOL reduced the KATP currents in Kir6.1(wt/VM)CS mice in both skeletal muscle and bone cells but was not effective in the SUR2([A478V]) mice fibers. These data indicate a subunit specificity of ZOL action that is important for appropriate CS therapies.

Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent KATP Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome

Scala, Rosa;Maqoud, Fatima;Perrone, Maria Grazia;Scilimati, Antonio;Tricarico, Domenico
2023-01-01

Abstract

Cantu syndrome (CS) is caused by the gain of function mutations in the ABCC9 and KCNJ8 genes encoding, respectively, for the sulfonylureas receptor type 2 (SUR2) and the inwardly rectifier potassium channel 6.1 (Kir6.1) of the ATP-sensitive potassium (KATP) channels. CS is a multi-organ condition with a cardiovascular phenotype, neuromuscular symptoms, and skeletal malformations. Glibenclamide has been proposed for use in CS, but even in animals, the drug is incompletely effective against severe mutations, including the Kir6.1(wt/V65M). Patch-clamp experiments showed that zoledronic acid (ZOL) fully reduced the whole-cell KATP currents in bone calvaria cells from wild type (WT/WT) and heterozygous Kir6.1(wt/V65M)CS mice, with IC50 for ZOL block < 1 nM in each case. ZOL fully reduced KATP current in excised patches in skeletal muscle fibers in WT/WT and CS mice, with IC50 of 100 nM in each case. Interestingly, KATP currents in the bone of heterozygous SUR2(wt/A478V) mice were less sensitive to ZOL inhibition, showing an IC50 of similar to 500 nM and a slope of similar to 0.3. In homozygous SUR2(A478V/A478V) cells, ZOL failed to fully inhibit the KATP currents, causing only similar to 35% inhibition at 100 mu M, but was responsive to glibenclamide. ZOL reduced the KATP currents in Kir6.1(wt/VM)CS mice in both skeletal muscle and bone cells but was not effective in the SUR2([A478V]) mice fibers. These data indicate a subunit specificity of ZOL action that is important for appropriate CS therapies.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/430591
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact